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Abstract
Diisocyanates (dNCOs) are low molecular weight chemical sensitizers that react with autologous 
proteins to produce neoantigens. dNCO-haptenated proteins have been used as immunogens for 
generation of dNCO-specific antibodies and as antigens to screen for dNCO-specific antibodies in 
exposed individuals. Detection of dNCO-specific antibodies in exposed individuals for diagnosis 
of dNCO asthma has been hampered by poor sensitivities of the assay methods in that specific IgE 
can only be detected in approximately 25 % of the dNCO asthmatics. Apart from characterization 
of the conjugates used for these immunoassays, the choice of the carrier protein and the dNCO 
used are important parameters that can influence the detection of dNCO-specific antibodies. 
Human serum albumin (HSA) is the most common carrier protein used for detection of dNCO 
specific-IgE and -IgG but the immunogenicity and/or antigenicity of other proteins that may be 
modified by dNCO in vivo is not well documented. In the current study, 2,4-toluene diisocyanate 
(TDI) and 1,6-hexamethylene diisocyanate (HDI) were reacted with HSA and human hemoglobin 
(Hb) and the resultant adducts were characterized by (i) HPLC quantification of the diamine 
produced from acid hydrolysis of the adducts, (ii) 2,4,6-trinitrobenzene sulfonic acid (TNBS) 
assay to assess extent of cross-linking, (iii) electrophoretic migration in polyacrylamide gels to 
analyze intra- and inter-molecular cross-linking, and (iv) evaluation of antigenicity using a 
monoclonal antibody developed previously to TDI conjugated to Keyhole limpet hemocyanin 
(KLH). Concentration-dependent increases in the amount of dNCO bound to HDI and TDI, cross-
linking, migration in gels, and antibody-binding were observed. TDI reactivity with both HSA and 
Hb was significantly higher than HDI. Hb-TDI antigenicity was approximately 30 % that of HSA-
TDI. In conclusion, this data suggests that both, the extent of haptenation as well as the degree of 
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cross-linking differs between the two diisocyanate species studied, which may influence their 
relative immunogenicity and/or antigenicity.
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Introduction
Diisocyanates (dNCOs) are highly reactive chemicals used as cross-linking agents in the 
manufacture of polyurethane products such as paints, elastomers, and adhesives1–3. They are 
potent sensitizers and are a commonly reported cause of occupational chemical 
hypersensitivity reactions including asthma4,5. 2, 4-Toluene diisocyanate (2, 4-TDI) and 1, 
6-hexamethylene diisocyanate (HDI) are among the most widely used isocyanates. Both 
have high vapor pressures6 and exposure often occurs through inhalation of vapors and 
aerosols during spraying operations at workplaces.
Immune-mediated hypersensitivity reactions to dNCOs include allergic rhinitis7, asthma8, 
hypersensitivity pneumonitis9,10 and allergic contact dermatitis11. Although most reported 
cases of isocyanate sensitization occur at workplaces13,14, it has been suggested that non-
occupational exposure to the general public may also occur through use of “do-it-yourself” 
free diisocyanate containing commercial products such as polyurethane foams and 
sprays15,16. Once allergic sensitization to isocyanates occurs, asthmatic reactions may be 
triggered by exceedingly minute concentrations of isocyanates5,17,18.
Diisocyanates are low-molecular-weight compounds that must first react with autologous 
proteins to produce a functional antigen19. The fate of the dNCO in the body and the protein 
adducts responsible for immunological sensitization remain unknown8. Apart from reacting 
with proteins at the site of exposure, protein conjugation by dNCOs may also occur via 
glutathione (GSH) thiocarbamate intermediates. GSH is abundant in the airways and 
Wisnewski and colleagues demonstrated that albumin can be conjugated to TDI and HDI by 
GSH-TDI and GSH-HDI, respectively20. HSA is the most common carrier protein used for 
dNCO antibody immunoassays21 due to its prevalence in plasma22 to form dNCO adducts. 
Other molecules, such as keratin 1822, tubulin23, and the peptide glutathione24, have been 
found to be modified by dNCO exposure. Sabbioni and coworkers reported MDI bound to 
the N-terminal valine of Hb in MDI exposed rats and proposed Hb–MDI as a biological 
marker of MDI exposure25.
There is currently no simple diagnosis for dNCO-induced occupational asthma (OA)26. One 
approach that can potentially be used is testing for dNCO-specific IgE from a worker’s 
serum. For confirmation of the diagnosis of dNCOas the etiological agent of the 
occupational asthma, these assays have been reported to be specific (96–98%), but not 
sensitive (18–27%)27. These low sensitivities have been attributed to both assay limitations 
and potential IgE-independent dNCO asthma mechanisms21. Immunoassay standardization 
is critical for improvement of immunoassay sensitivity and comparison of results across 
studies19. A number of factors that may confound results from these immunoassays include 
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the choice of dNCO used, the carrier protein employed, dNCO–protein reaction conditions, 
and post-reaction processing and characterization of the haptenated protein.
Wisnewski et al, in separate studies, reported differences in reactivity between TDI and HDI 
toward glutathione (GSH). Albumin was conjugated to TDI and HDI by GSH-TDI28 and 
GSH-HDI20, respectively. From these two reports, the kinetics of GSH-HDI mediated 
albumin carbamoylation was substantially slower compared with those of GSH-TDI. The 
hydrolysis of aliphatic isocyanates is also much slower than aromatic isocyanates. However, 
the nature and extent of HDI and TDI conjugation, in vivo, to serum proteins has not yet 
been reported. Diisocyanate haptenated proteins have been used both to produce specific 
antibodies29,30 and to screen for dNCO specific antibodies in workers’ sera for diagnosis of 
OA31.However, these conjugates are often poorly characterized and non-standardized.
Our previous work focused on characterization of methylene diphenyl diisocyanate (MDI)-
HSA and MDI-Hb conjugates32. Although HSA is the most common carrier protein used for 
dNCO antibody immunoassays21,22, other proteins, however, have also been found to be 
potentially modified by dNCO exposure22–25,33,34but the immunogenicity of adducted 
proteins other than albumins has not been reported.
One hypothesis is that the lack of a standard characterization protocol for conjugates used to 
screen for dNCO specific antibodies in workers' sera is contributing to the reported low 
sensitivities and variability of these assay methods. Our previous work on MDI shed light on 
the need to use multiple methods to characterize these conjugates. In the present study we 
extend the characterization of the dNCO-protein conjugates from MDI to understand 
reactivity differences among dNCOs such as TDI and HDI that can impact assay 
sensitivities and standardization protocols. Quantification of the amount of TDI and HDI 
bound per mole protein was conducted by analyses of the corresponding hydrolysis products 
following assay hydrolysis of the conjugate, derivitization of the diamines and HPLC 
florescence detection32. Cross linking was evaluated using the 2, 4, 6-trinitrobenzene 
sulphonic acid (TNBS) assay, which is a primary amine-specific spectrophotometric probe. 
TNBS reacts with primary amines in proteins to produce a complex that absorbs at 420 nm. 
Loss of TNBS reactivity in dNCO-conjugated proteins occurs only when the dNCO cross-
links two amine sites. This method, though not very sensitive, is very specific because only 
primary amines, the predominant sites found to be conjugated and cross-linked by dNCOs, 
react with TNBS. Gel electrophoresis was also used to qualitatively evaluate the extent of 
conjugation and cross linking in dNCO conjugated proteins. Under denaturing conditions 
intermolecular cross-linked proteins and highly substituted proteins have a larger molecular 
size in comparison to unconjugated protein and these tend to migrate slower. On the other 
hand, intramolecular cross-linking may prevent complete protein denaturation resulting in 
the migration similar to that of a smaller molecule that migrates faster. Proteomic mass 
spectrometry was employed to delineate TDI binding sites on Hb. Acrylonitrile adducted Hb 
and trimellitic anhydride (TMA)-adducted Hb were demonstrated to be antigenic35,36, so it 
is crucial to understand the reactivity of Hb to different dNCOs as well as to dNCO specific 
monoclonal antibodies relative to a well-documented dNCO reactive protein HSA.
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Materials and methods
Chemicals
Unless otherwise specified, all reagents were acquired from Sigma–Aldrich (St. Louis, MO, 
USA) and used without further purification. Dichloromethane (reagent grade) was purchased 
from J.T. Baker/Avantor Performance Materials (Center Valley, PA, USA). Sodium tetra 
borate, sodium hydroxide, hydrochloric acid, 98 % sulfuric acid, and N-acetyl glycine were 
purchased from Fisher Scientific (Fair Lawn, NJ, USA).
Preparation of TDI–HSA/Hb adducts
TDI–protein adducts were prepared as described previously for MDI-HSA/Hb conjugates32. 
Briefly, 0.5 mg/ml protein solutions were prepared in 0.01 M PBS (pH 7.4). TDI (42.3 µl) 
was dissolved in 1 ml dry acetone and diluted ten times to make stock solution for 40:1 TDI: 
protein. Serial dilutions of TDI in acetone were performed to make stock solutions for 10:1, 
5:1 and 1:1 TDI:protein. Fifty µL TDI stock solution was added to 5 ml of 0.5 mg/ml protein 
with mixing, resulting in TDI:protein molar conjugation ratios of 1:1, 5:1, 10:1, and 40:1. 
Samples were then incubated at room temperature (RT) for 1 h with mixing. Following 
incubation, samples were dialyzed for 18 h at 4°C against 4 L of distilled deionized water 
using 12,000–14,000 MWCO dialysis tubing (Spectrum Laboratories, Inc., Rancho 
Dominguez, CA) and stored at 4°C until analysis.
Preparation of HDI–HSA/Hb adducts
For preparation of HDI–protein adducts, 0.5 mg/ml protein solutions were prepared in 0.01 
M PBS (pH 7.4). HDI (47.3 µL) was dissolved in 1 ml dry acetone and diluted ten times to 
make stock solution for the 40:1 HDI:protein conjugation ratio. Serial dilutions of HDI in 
acetone were prepared to make solutions for 10:1, 5:1 and 1:1 HDI:protein conjugation 
ratios. Conjugations, dialysis and sample storage were performed as described for TDI 
samples.
Analysis of number of moles of dNCO bound per mole protein
TDI/HDI-conjugated proteins (2 ml aliquots) were hydrolyzed by incubating with 1 ml of 3 
M H2SO4 at 100°C for 16 h. Toluene diamine (TDA) and hexamethylene diamine (HDA) 
standards (Sigma–Aldrich, St. Louis, MO, USA) were spiked into protein standards (1–
16,000 ng/ml) and were run in parallel with conjugates. Following hydrolysis, samples and 
standards were cooled to RT and 5 ml of saturated sodium hydroxide was added. Samples 
were vortexed, and put in an ice bath to cool for 10 min. The resulting TDA and HDA from 
samples and standards were extracted into 6 ml of dichloromethane and the solvent was 
subsequently evaporated at 40°C under N2 to 1 ml. The dichloromethane extracts were then 
back-extracted into 500 µl of 0.5 % H2SO4. Saturated borate buffer (250 µl, pH 8.5) and 450 
µl of acetonitrile were added to 250 µl of H2SO4 extract and vortexed for 1 min. 
Fluorescamine (50 µl of 14.4 mg/ml in acetonitrile) was added. This was vortexed for 1 min, 
and 100 µl was injected onto a Supelco LC-SI C18 column (25 cm 4.6 mm, 5 µm, Supelco, 
Bellefonte, PA, USA). Samples and standards were analyzed on a Shimadzu Prominence 
high-performance liquid chromatography system (HPLC) (Shimadzu, Columbia, MD, USA) 
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consisting of an online vacuum degasser (model DGU-20A5), a quaternary pump (model 
LC-20AT), an auto sampler (model SIL-10AD-VP), and a fluorescence detector (model 
RF-10AXL). The HPLC system was controlled by EZ Start software version 7.3 (Lab 
Alliance, State College, PA, USA). Samples and standards were eluted from the column at 1 
ml/min over 20 min using a linear gradient of 10% to 50% acetonitrile/water over 13 min 
and held at 50% for 5 min. The resulting TDA/HDA–fluorescamine complex was excited at 
410 nm, and emission was measured at 510 nm.
Assessment of cross-linking: TNBS assay
The trinitrobenzene sulfonic acid (TNBS) assay was used to evaluate the extent of cross-
linking in TDI–HSA and HDI-HSA conjugates37. TNBS (5%, w/v) was diluted 1:5.48 with 
0.1 M borate buffer, pH 9.3. To 500 µl of sample, 12.5 µl of diluted TNBS was added, 
mixed and incubated for 30 min at RT. Absorbance at 420 nm was measured on a Beckman 
Coulter spectrophotometer (model DU 800, Beckman Coulter, Somerset, NJ, USA).
Assessment of cross-linking: Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE)
For denaturing gels, HSA, Hb, and TDI/HDI–HSA/Hb conjugates were mixed with 
Laemmli sample buffer containing 2-mercaptoethanol. Samples were run on 8% and 12% 
polyacrylamide gels. Following electrophoretic separation of proteins, the gels were stained 
with Imperial™ protein stain (Pierce, Rockford, IL, USA) and destained in water. 
Unmodified/unconjugated HSA, Hb and Bio-Rad pre-stained molecular weight markers 
(Life Science, Hercules, CA) were used for relative molecular weight determination.
Trypsin digestion of hemoglobin samples
For identification of TDI conjugation sites on Hb by ultra-performance liquid 
chromatography quadruple time-of-flight mass spectrometry (UPLC–qTOF MS), 200-µl 
aliquots of TDI–Hb samples were incubated with tributyl phosphine for 30 min at RT to 
reduce the disulfide bonds, followed by alkylation with iodoacetamide for 1 h at RT. 
Alkylation was quenched by further addition of tributyl phosphine for 15 min at RT. Porcine 
trypsin in 25 mM NH4HCO3 was then added at a 40:1 (protein/trypsin) ratio. Samples were 
incubated overnight at 37°C. The next day, 12 µL of 10 % triflouroacetic acid (TFA) was 
added to stop trypsin digestion.
Ultra-performance liquid chromatography (UPLC)
Tryptic peptides of Hb and TDI–Hb were separated on a Waters nanoACQUITY UPLC 
system (Waters, Milford, MA, USA). Aliquots (1 µl) of the digest mixture were injected and 
trapped/desalted on a 5-µm Symmetry C18 trapping column (180 µm × 20 mm) with 
99.5/0.5 A/B (A: 0.1% formic acid; B: 0.1% formic acid in acetonitrile) at a flow rate of 15 
µl/min for 1 min. Separation was performed on a 1.7-µm BEH130 C18 analytical column 
(100 µm × 100 mm) using gradient elution at a flow rate of 400 nl/min and a gradient of 
99:1 to 60:40 A/B over 90 min.
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Tandem Mass Spectrometry (MS/MS) analysis of Hb peptides
The eluent from the UPLC system was directed to the nano-electrospray source of a Waters 
SYNAPT MS qTOF mass spectrometer. Positive ion nano-electrospray was performed using 
10-µm Pico-Tip (Waters) emitters held at a potential of +3.5 kV. The cone voltage was held 
constant at +40 V for all experiments. Dry nitrogen desolvation gas was supplied to the 
instrument via a nitrogen generator (NitroFlowLab, Parker Hannifin, Haverhill, MA, USA). 
[Glu] 1-Fibrinopeptide B (100 fmol/µl in 75:25 A/B) was supplied to an orthogonal 
reference probe, and the [M+2H]2+ ion (m/z 785.84265u) was measured as an external 
calibrant at 30-s intervals. Ultra-high purity (UHP) argon was used as collision gas. Spectra 
were acquired in an “MSe” fashion38,39. Alternating 1-s mass spectra were acquired. The 
collision energy was set to 6 eV (1-s low energy scan) and a 15- to 30-eV ramp (1-s high 
energy scan).
Data analysis for TDI binding sites on Hb
Data were analyzed with BioPharmaLynx version 1.2 (Waters), a software program for 
analysis of peptide mass maps and identification of sites of modification on known protein 
sequences. Identification of an isocyanate binding site involved observing a potential 
peptide–dNCO conjugation product with less than 30 ppm m/Dm mass error in the analyte 
peptide mass map, comparing analyte and control peptide mass map from unmodified Hb 
showing that observed m/z and chromatographic retention time are unique to analyte, and 
observing MS/MS data containing bn- and yn-type ions consistent with the assigned 
sequence and modifier.
Immunoassay for conjugates: ELISA for TDI-HSA/Hb
Binding of IgG1 monoclonal antibody (mAb) 60G2 raised against TDI-KLH30 to TDI-
conjugated HSA and Hb was analyzed using an indirect enzyme-linked immunosorbent 
assay (ELISA). The development and characterization of the 60G2 mAb has been previously 
described by Ruwona et al30. Ninety-six-well plates (Corning, NY, USA) were coated with 
TDI-protein conjugates overnight at 4°C. After washing three times with PBST (PBS with 
0.05% Tween 20), plates were blocked with 3% skim milk/PBST (SMPBST) for 1 h at 
37°C. Plates were then incubated on a shaker for 1 h with 2 µg/ml 60G2 mAb at RT, washed 
three times with PBST and incubated for 1 h at 37°C with alkaline phosphatase conjugated 
AffiniPure goat, anti-mouse IgG (H+L) (Promega, Madison, WI) diluted 1:5000 (v/v) in 
SMPBST. Following incubation, plates were washed 3 times with PBST and binding of the 
60G2 mAb to the conjugates was visualized using 0.5 mg/ml p-nitrophenyl phosphate 
(Sigma–Aldrich, CAS Number 4264-83-9) in alkaline phosphatase substrate. The optical 
density was measured at 405 nm after 30 min using a Molecular Devices SpectraMax M4 
Multi-mode Micro plate Reader (Sunnyvale, CA, USA)
Statistical analysis
Data are presented as mean and standard deviation (SD). Analysis of variance (ANOVA) 
was employed for comparing the effect of dNCO and protein on the extent of conjugation 
and crosslinking on proteins. Differences were considered significant at a p < 0.05. N = 3/
group, where N is number of replicates.
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Results
Mapping TDI binding sites on Hb
TDI-Hb conjugates were digested with trypsin, and resultant peptides were analyzed by 
UPLC–MS/MS to determine TDI binding sites. Examination of the tandem mass spectra of 
the tryptic peptides allowed assignment of conjugation sites on Hb as previously 
described32. Hb has 2 alpha and 2 beta subunits and mass spectrometry allowed 
identification of the parent subunit from which each binding site originated. Table 1 shows 
the concentration-dependent specific binding sites identified for TDI on Hb.
A TDI concentration dependent increase in the number of binding sites was observed and a 
total of eight binding sites were identified at the highest concentration of TDI used, 
including the N-terminal valine on both the alpha and beta chains. TDI bound to three 
lysines on the alpha chain and three additional lysines on the beta chain. At the lowest TDI 
concentration used, only the two N-terminal valines of the alpha and beta chains were 
bound. Increasing TDI concentrations increased the number of sites bound to a maximum of 
eight at 40:1 TDI:Hb.
Quantification of TDI and HDI binding in Hb and HSA
TDI and HDI-conjugated HSA and Hb were hydrolyzed under strong acidic conditions and 
the resultant TDA and HDA were derivatized with fluorescamine and quantified using 
HPLC. Quantification of the number of moles of TDI and HDI bound to Hb and HSA is 
reported in Table 2. On a per mole basis, TDI was more reactive to both Hb and HSA than 
HDI over the entire concentration ranges used in this study. This agrees with findings from 
Wisnewski et al. who found that the rate of HSA carbamoylation from TDI-GSH derived 
TDI was higher than carbamoylation from HDI-GSH derived HDI20,28. Table 2 also 
demonstrates that HSA was more reactive to TDI than Hb. A similar trend was noted for 
HDI.
Cross-linking in TDI–and HDI-HSA: TNBS assay
Table 3 shows a concentration-dependent loss of available primary amines with increasing 
TDI and HDI concentrations and, thus, an increase in the amount of dNCO cross-linking of 
protein residues32. At TDI and HDI concentrations ranging from 1:1 to 10:1, the degree of 
cross linking is not statistically different between the 2 diisocyanates. However at 40:1 
dNCO: HSA, TDI has a significantly higher degree of cross linking than HDI (P-value < 
0.01). The TNBS assay could not be used to evaluate cross-linking in Hb conjugates because 
of spectral interference at 420 nm, the wavelength at which the absorbance of the complex 
between TNBS and primary amine is measured.
Qualitative assessment of conjugation and crosslinking in TDI/HDI–HSA and TDI/HDI– Hb: 
Gel electrophoresis
Polyacrylamide gel electrophoresis was used to evaluate the extent of binding and cross-
linking. Intermolecular cross-linked and highly substituted proteins will migrate at a slower 
rate than the unconjugated protein, whereas extensive intramolecular cross-linking may 
prevent complete protein denaturation, causing an apparent migration of a molecule smaller 
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that the unconjugated protein. Figure 1 shows an 8% SDS– PAGE gel of 0.5 mg/ml HSA 
reacted to TDI. Significant spreading of the HSA band was observed at the 40:1 TDI:HSA 
conjugation ratio. Figure 2 is a 12% denaturing gel of 0.5 mg/ml Hb reacted to TDI. 
Denaturation of Hb resulted in the incomplete dissociation of the alpha and beta subunits 
that migrated at molecular weights of approximately 14 kDa 28 kDa. Shift in migration due 
to conjugation to TDI was not observed. In contrast, HDI-HSA and HDI-Hb conjugates 
produced band spreading and shifts in migration/band spreading for both HSA and Hb 
conjugates. (Fig. 3 and 4).
ELISA assessment of TDI-HSA and TDI-Hb
HDI-Hb conjugates reactivity to antibodies was not evaluated due to the lack of an HDI 
specific antibody. Although there is cross reactivity between HDI and monoclonal 
antibodies raised against TDI, the reactivity was too low and close to detection limit to make 
any quantitative analysis in agreement with HPLC results. Binding of IgG mAb 60G2 to 
TDI-conjugated HSA and Hb was analyzed using an indirect enzyme-linked immunosorbent 
assay (ELISA). Figure 5 shows the immunoassay results of conjugated proteins following 
titration into the ELISA plate at protein concentrations from 97.66 ng/ml to 25 µg/ml. 
Immuno reactivity of 60G2 to the conjugated Hb was higher at 40:1 TDI-protein than 10:1 
in both HSA and Hb conjugates. 60G2 was more reactive to TDI-HSA than TDI-Hb at both 
40:1 and 10:1 TDI-protein.
Discussion
Our previous study employed several techniques to evaluate MDI-HSA and MDI-Hb 
conjugates32. In the current study, we extended use of this methodology to compare TDI–
HSA, TDI–Hb, HDI-HSA, and HDI-Hb conjugates. The objective was to compare the 
extent of conjugation of TDI and HDI to proteins (HSA and Hb), evaluate differences in the 
extent of cross-linking using the TNBS assay between TDI and HDI on HSA, and assess 
reactivity of TDI conjugated HSA and Hb with a monoclonal antibody (IgG 60G2 mAb) 
that recognizes TDI conjugated proteins. The methodology used herein is relevant for the 
characterization and standardization of dNCO haptenated protein for specific antibody 
detection. Although knowledge of specific sights bound at lower conjugation ratios may 
have value in the development of biomonitoring of dNCO conjugates in biological fluids, 
the measurement and characterization of in vivo formed species is beyond the scope of the 
present work. Differences in reactivity between TDI and HDI conjugated to HSA and Hb 
were observed using the HPLC quantification of moles dNCO bound per mole protein. HSA 
was more reactive to both TDI and HDI than Hb. This may be indicative of the structural 
differences between the two proteins. Hb, with four polypeptide subunits (two alpha and two 
beta) and an iron-containing porphyrin ring, may mask potential binding sites, thus affecting 
its reactivity with dNCOs. This contrasts sharply with HSA, a single polypeptide with 17 
pairs of disulfide bridges and 1 free cysteine. TDI was more reactive to both HSA and Hb 
than HDI at pH 7.4. These results agree with earlier findings where HSA was found to be 
the most modified protein in the blood of dNCO exposed subjects21. MS/MS was used to 
delineate specific TDI binding sites on Hb. A concentration-dependent increase in the 
number of binding sites was observed across the entire TDI concentration range employed. 
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Only the N terminal valines on both the alpha and beta subunits were observed at 1:1 TDI: 
Hb and these were conserved at all concentrations studied, suggesting that these sites are the 
kinetically favored reactive sites. Non-terminal amino acids of the beta subunit were bound 
by TDI only from 10:1 TDI:Hb concentrations and higher, while non-terminal amino acid 
binding sites on the alpha subunit were observed at 5:1 TDI:Hb. The non-terminal TDI 
binding sites observed on Hb were all lysine residues, specifically lysines 11, 16, and 40 of 
the alpha subunit and lysines 17, 144, and 61 of the beta subunit. Some of the TDI binding 
sites observed in this study were comparable to the MDI binding sites reported in our 
previous study32. In addition to the N-terminal valines of the alpha and beta subunits, lysine 
66 was also observed at 1:1 MDI:Hb. Only lysine 40 of the alpha subunit and lysine 61 of 
the beta subunit were bound by both MDI and TDI. Lysines 11 and 16 of the alpha subunit 
and lysines 17 and 144 of the beta subunit were only observed in TDI. In contrast, lysine 7 
of the alpha subunit and lysines 8, 65 and 66 of the beta subunit were only observed with 
MDI. The differences in the binding sites between MDI and TDI can give an insight into the 
possibility for conformational and structural differences in the resultant conjugates, which 
may potentially affect their antigenicity and immunogenicity.
The TNBS assay, which has traditionally been used to assess chemical adduction with 
amino groups40, was employed in this study to evaluate cross-linking in TDI-HSA and HDI-
HSA conjugates. A concentration dependent loss of available primary amines with 
increasing TDI and HDI concentrations was observed, indicating an increase in the amount 
of dNCO cross-linking of protein residues. At lower TDI and HDI concentrations (1:1–10:1 
TDI/HDI: HSA), the degree of cross-linking was similar for both dNCOs. At 40:1 dNCO: 
HSA, TDI had a higher degree of cross-linking than HDI. A 62% loss of primary amine 
reactivity was observed at 40:1 TDI:HSA compared with a 48% loss of amine reactivity at 
40:1 HDI:HSA (P < 0.01). A similar comparison could not be made for hemoglobin 
conjugates due to spectral interference at 420 nm, the wavelength at which the absorbance of 
the TNBS-amine complex was measured.
The ability of the TDI conjugates to be bound by TDI-specific antibody was evaluated using 
an indirect ELISA format. The ELISA format employed in the current study used an anti 
TDI–protein IgG that was produced in our lab against TDI-KLH17 as the primary antibody 
and an alkaline phosphatase-labeled anti-IgG as the detection antibody. Both TDI-HSA and 
TDI-Hb reacted to the anti-TDI-protein monoclonal antibody, indicating that TDI 
conjugated Hb can be antigenic. TDI-Hb antigenicity with the 60G2 mAb was however 30% 
lower than that observed for TDI-HSA. This is in agreement with HPLC results where TDI 
binding to HSA was significantly higher than to Hb suggesting that the absolute number of 
moles of dNCO bound rather than the specific protein bound is a greater determinant for 
recognition by the 60G2 mAb. The immunogenicity or antigenicity of in vivo dNCO-
adducted hemoglobin has not yet been reported in the literature, although our data suggest 
that dNCO haptenated HSA is superior to conjugated Hb for the detection of dNCO specific 
antibody.
Cross-linking and extent of conjugation was visualized using denaturing gel electrophoresis. 
Alteration of migration and band spreading was evident for both HDI and TDI conjugated 
HSAs at the highest conjugation ratio, however, a clear migration shift/band spreading was 
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only evident in HDI:HSA at the lower binding ratios (Figures 1 and 3). Hemoglobin 
subunits did not completely dissociate under denaturing conditions as evidenced by the 
protein band at approximately 28 kDa. Shift in migration of TDI bound Hb subunits was not 
observed, and only clearly observed at the highest HDI conjugation ratio of 40:1 (Figures 2 
and 4). These finding are in contrast to what was previously observed for MDI, where clear 
conjugation-dependent shifts in migration were observed down to a 1:1 conjugation ratio.32 
One possible explanation for the differences seen between SDS-Page between that observed 
for HDI, MDI and TDI bound proteins may be that location of the 2 TDI NCO groups 
located on the benzene ring are spatially closer to each other than in MDI or HDI which may 
produce differences in comparative migration of the conjugates in the SDS-Page gels.
Increasing molar ratio for conjugation increased extent of conjugation, degree of cross-
linking, gel migration and reactivity with dNCO specific monoclonal antibody binding. It is 
therefore difficult to dissect the specific influences of intra- and intermolecular cross-linking 
from total dNCO bound on the overall antigenicity of the resultant conjugates.
The bifunctional electrophilic nature of the diisocyanates make it very difficult to dissect out 
the components critical to dNCO specific antibody recognition.
Increases in total amount of dNCO bound, intra- and intermolecular crosslinking, and dNCO 
self-polymerization on proteins, and as well as recognition by the 60G2 mAb all increase 
were demonstrated with increasing conjugation ratios of dNCO:protein. The mAb 60G2 is 
extremely well characterized with respect to binding specificity (30). It recognizes both 2,4-
TDI and 2,6-TDI bound HSA, bound mouse serum albumin, and bound keratin. It has slight 
reactivity toward MDI-HSA, HDI-HSA and HSA conjugated to 2,5- and 3,4- dimethyl 
phenylisocyanate. It has no reactivity toward phenyl isocyanate, 2-toluene isocyanate, 4-
toluene isocyanate or toluene diisothiocyanates. Although, dNCO specific IgE and IgG from 
dNCO exposed individuals was not tested against the various dNCO conjugated proteins, 
others have reported that recognition by patient sera antibodies is dependent on 
immunoassay procedure, conjugation method and predominant exposure dNCO form to that 
individual41,42. Comparison of specific antibody prevalence in dNCO workers is difficult in 
the absence of detailed dNCO-HSA characterization. Until the relative contribution of the 
multiple dNCO conjugation products to dNCO immunogenicity and antigenicity can be 
determined, we believe that dNCO antigen preparations used for standardized screening of 
workers’ sera or research applications should undergo as complete quantitative chemical 
characterization as possible similar to that outlined in the present manuscript.
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Figure 1. 
An 8% SDS– PAGE denaturing gel of 0.5 mg/ml HSA reacted to TDI. Lane 1 is the 
molecular weight marker, lane 2 is HSA, and lanes 3, 4, 5, and 6 are 40:1, 10:1, 5:1, and 1:1 
TDI: HSA, respectively.
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Figure 2. 
A 12% denaturing gel of 0.5 mg/ml Hb reacted to TDI. Lane 1 is the molecular weight 
marker, lane 2 is Hb, and lanes 3, 4, 5, and 6 are 40:1, 10:1, 5:1, and 1:1 TDI: Hb, 
respectively.
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Figure 3. 
An 8% denaturing gel of 0.5 mg/ml HSA reacted to HDI. Lane 1 is the molecular weight 
marker, lane 2 is HSA, and lanes 3, 4, 5, and 6 are 40:1, 10:1, 5:1, and 1:1 HDI: HSA, 
respectively.
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Figure 4. 
A 12% denaturing gel of 0.5 mg/ml Hb reacted to HDI. Lane 1 is the molecular weight 
marker, lane 2 is Hb, and lanes 3, 4, 5, and 6 are 40:1, 10:1, 5:1, and 1:1 HDI: Hb, 
respectively.
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Figure 5. 
Comparison of 60G2 mAb binding to TDI conjugated Hb and TDI conjugated HSA. ELISA 
absorbances curves for 40:1 and 10:1 TDI:protein conjugation ratios at multiple dilutions 
demonstrate superior binding of the mAb to TDI-HSA on a per mass basis..
Mhike et al. Page 18
J Immunol Methods. Author manuscript; available in PMC 2017 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Mhike et al. Page 19
Table 1
Amino acid specific binding sites observed for TDI on hemoglobin
1:1 5:1 10:1 40:1
Alpha subunit
Val 1 x x x x
Lys 11 x x x
Lys 16 x x
Lys 40 x
Beta subunit
Val 1 x x x x
Lys 17 x x
Lys 144 x x
Lys 61 x
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Table 2
Moles of TDI and HDI bound per mole of Hb or HSA quantified using HPLC
dNCO: protein Average moles of dNCO bound Average moles of dNCO bound
TDI: HSA HDI: HSA TDI: Hb HDI: Hb
1:1 0.51 ± 0.56 0.04 ± 0.41** 0.15 ± 0.15## 0.02 ± 0.21**
5:1 2.65 ± 0.23 0.44 ± 0.45** 0.57 ± 0.02## 0.13 ± 0.23**
10:1 5.06 ± 0.43 0.82 ± 0.36* 1.48 ± 0.09## 0.32 ± 0.60**
40:1 12.86 ± 0.56 2.79 ± 0.40* 4.31 ± 0.06## 1.03 ± 0.59**
Extent of HDI binding to HSA is statistically different than TDI binding (*P<0.05; **P<0.01) Comparison of dNCO binding to HSA vs. to Hb.
(##P<0.01)
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Table 3
Cross-linking in TDI-HSA and HDI-HSA using loss of absorbance: TNBS assay.
dNCO: protein molar ratio Loss of TNBS Amine reactivity (%)
HDI: HSA 2,4-TDI: HSA
Negative control 0.00 ± 0.00 0.00 ± 0.00
1:1 25.46 ± 2.34 18.04 ± 3.98
5:1 30.24 ± 2.89 31.47 ± 3.57
10:1 32.88 ± 3.14 39.92 ± 4.14
40:1 48.35 ± 3.76 62.42 ± 4. 18**
**
Extent of TDI cross-linking statistically different than HDI (P<0.01)
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